REG - Beximco Pharma. - Results for the year ended 30 June 2024

Beximco PharmaceuticalsAnnouncement

07/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241107:nRSG2426La&default-theme=true

RNS Number : 2426L  Beximco Pharmaceuticals Ltd  07 November 2024

 

7 November 2024

 

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation 596/2014 which is part of English Law
by virtue of the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain.

 

BEXIMCO PHARMACEUTICALS LIMITED.

 

Results for the year ended 30 June 2024

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM
Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of
generic pharmaceutical products and active pharmaceutical ingredients, today
announces its audited results for the year ended 30 June 2024.

 

Financial Highlights (consolidated)

 

·      Net sales increased 13.1% to Bangladesh Taka ("BDT") 44,391.6m /
£286.6m (2022-23: BDT 39,266.7m / £288.6m)

o  Domestic sales increased 13.5% to BDT 41,433.3m / £267.5m (2022-23: BDT
36,503.4m / £268.3m)

o  Export sales increased 7.1% to BDT 2,958.4m / £19.1m (2022-23: BDT
2,763.2m / £20.3m)

·      Profit after tax increased 29.7% to BDT 5,866.8m / £37.9m
(2022-23: BDT 4,524.5m / £33.3m)

·      EPS for the year amounted to BDT 13.07 (2022-23: BDT 10.34)

·      Recommended 40% cash dividend (BDT 4.00 per share)

 

Operational Highlights

 

·      Launched 30 new products in Bangladesh market

·      Completed 37 new registrations of 31 products across 11 countries

·      Received two product approvals from the US FDA

o  Hydroxyzine Pamoate capsule (an antihistamine drug), and Carbidopa tablet
(a medication for the treatment of Parkinson's disease)

·      Obtained approvals from the Therapeutic Goods Administration
(TGA), Australia for two products

o  Mometasone nasal spray (a corticosteroid), and Hyoscine Butylbromide
tablet (an antispasmodic drug)

·      Launched Flecainide tablets (50 mg, 100 mg, and 150 mg) and
Nebivolol tablets (2.5 mg, 5 mg, 10 mg, and 20 mg) in the US

·      Launched Ketorolac 10 mg tablet - the 3rd oral solid dose (OSD)
product in the Canadian market

·      Won Bangladesh's National Export Trophy (Gold) for a record ninth
time

 

Post Period Activity

·      Launched three new products in the domestic market

·      Completed 18 new product registrations across five countries

 

Beximco Pharma Managing Director Iqbal Ahmed commented:

 

"We have again delivered a strong set of results, including double digit
revenue growth and a 40% cash dividend for shareholders. Our performance this
year underscores the durability of the business despite challenging
macroeconomic factors. Following the appointment of an interim government in
Bangladesh, the political situation in the country has significantly
stabilised and, while rising inflation, increased interest rates, slower
economic growth and overall financial sector vulnerability pose challenges, we
remain committed to delivering high-quality, affordable healthcare solutions.
I firmly believe the Company is well prepared to navigate these challenges in
order to deliver value for shareholders and provide essential medicines for
patients."

 

Exchange rates of £1 = Taka 136.05 for 2022-23 numbers and £1 = Taka 154.90
for 2023-24 numbers have been used in this announcement.

 

This announcement is available in its entirety at
http://www.rns-pdf.londonstockexchange.com/rns/2426L_1-2024-11-6.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/2426L_1-2024-11-6.pdf) .

 

For further information please visit www.beximcopharma.com or enquire to:

 

S M Rabbur Reza, Chief Operating Officer

Tel: +880 2 58611001, Ext.20111

 

Mohammad Ali Nawaz, Chief Financial Officer

Tel: +880 2 58611001, Ext.20030

 

SPARK Advisory Partners Limited (Nominated Adviser)

Mark Brady / Andrew Emmott

Tel: +44 (0) 20 3368 3551 / 3555

 

SP Angel Corporate Finance LLP (Broker)

Matthew Johnson

Tel: +44 (0) 20 3470 0470

 

FTI Consulting

Simon Conway / Victoria Foster Mitchell/ Sam Purewal

Tel: +44 (0) 20 3727 1000

 

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

 

Beximco Pharma is a leading manufacturer and exporter of medicines based in
Bangladesh. Since its inception in 1976, the Company remains committed to
health and wellbeing of people across all the continents by providing access
to contemporary medicines. Company's broad portfolio of generics encompasses
diverse delivery systems such as tablets, capsules, liquids, semi-solids,
intravenous fluids, metered dose inhalers, dry powder inhalers, sterile
ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser
solutions, oral soluble films etc. The Company also undertakes contract
manufacturing for multinational and leading global generic pharmaceutical
companies.

 

Beximco Pharma′s state-of-the-art manufacturing facilities are certified by
global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin
America, among others and it has a geographic footprint in more than 50
countries. More than 5700 employees are driving the company towards achieving
its aspiration to be among the most admired companies in the world.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FR FLFFDLALRIIS